Who Needs Negotiation? US Rx Prices Are Falling – Thanks To Generics
Executive Summary
A Congressional Budget Office review of prescription drug pricing trends over the past decade shows a surprising fact: the average costs per prescription in the US is falling. That probably won’t change the political debate over drug prices – but maybe it should.
You may also be interested in...
Medicare Drug Price Negotiation Not A Major Threat To Pharma – Even If It Passes
Biopharma analysts discuss the likely impact of the drug pricing reform provisions in the Build Back Better legislation, which has hit a roadblock created by Democratic Senator Joe Manchin of West Virginia.
As US House Changes Hands, CMS May Face More Oversight Than FDA
Key Republican committee chairs on health issues are familiar faces, largely supportive of the US FDA’s approach to drug regulation. Implementation of the new pricing law, however, will get a lot more scrutiny.
Status Quo Senate Still Means Big Changes For FDA Oversight
The mid-term elections left the US Senate under Democratic leadership – but there are still big changes coming that may make life tougher on FDA and the brand name industry.